Incyte Corporation (INCY) Moves Lower on Volume Spike for January 11

Equities Staff |

Incyte Corporation (INCY) traded on unusually high volume on Jan. 11, as the stock lost 3.68% to close at $93.06. On the day, Incyte Corporation saw 3.22 million shares trade hands on 23,881 trades. Considering that the stock averages only a daily volume of 1.47 million shares a day over the last month, this represents a pretty significant bump in volume over the norm.

Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.

The stock has traded between $153.15 and $92.91 over the last 52-weeks, its 50-day SMA is now $100.18, and its 200-day SMA $119.36. Incyte Corporation has a P/B ratio of 11.17.

Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.

Headquartered in Wilmington, DE, Incyte Corporation has 980 employees and is currently under the leadership of CEO Herve Hoppenot.

For a complete fundamental analysis analysis of Incyte Corporation, check out’s Stock Valuation Analysis report for INCY.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit to learn more about Guild Investment’s Market Commentary and Adam Sarhan’s Find Leading Stocks today.

To get more information on Incyte Corporation and to follow the company’s latest updates, you can visit the company’s profile page here: INCY’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Pressure Biosciences Inc

Pressure BioSciences Inc is a biological life sciences research company. It is engaged in the development and commercialization of a platform technology called pressure cycling technology.

Private Markets


Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.